ArticleSchizophrenia research2018
Dimensional symptom severity and global cognitive function predict subjective quality of life in patients with schizophrenia and healthy adults.
Article in Schizophrenia research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Multigenetic Pharmacogenomics-Guided Treatment vs Treatment As Usual Among Hospitalized Men With Schizophrenia: A Randomized Clinical Trial.JAMA network open · 2023Trial
- PATIENT PATHWAYS TO UGANDA'S FIRST SPECIALISED EARLY INTERVENTION IN PSYCHOSIS SERVICE AND RELATION TO THEIR CLINICAL OUTCOMES.medRxiv : the preprint server for health sciences · 2026Article
- Exploring interrelationships between cognition, functioning and quality of life in schizophrenia spectrum disorders: a Bayesian analysis of networks.European archives of psychiatry and clinical neuroscience · 2026Article
- Why Not Rock the Boat? Deprescribing Anticholinergic Medications That Are No Longer Needed in Persons With Schizophrenia.Focus (American Psychiatric Publishing) · 2025Review
- The Effect of Multiple Oral Doses of a Glycine Transporter 1 Inhibitor, Iclepertin (BI 425809), on the Steady-state Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel: a Phase I Clinical Trial in Healthy Females.Clinical drug investigation · 2025Article
- Community-based recovery interventions for improving mental health in schizophrenia patients: a scoping review in Southeast Asia.BMC psychiatry · 2025Article
- Sleep and schizophrenia polygenic scores in non-affective and affective psychotic disorders.Psychological medicine · 2025Article
- Symptom contributors to quality of life in schizophrenia: Exploratory factor and network analyses.Schizophrenia research · 2024Article
- Insomnia in Chinese patients with chronic schizophrenia: prevalence, clinical correlates and relationship with cognitive impairment.Sleep & breathing = Schlaf & Atmung · 2023Article
- Valuable interaction with cognitive remediation and optimal antipsychotics for recovery in schizophrenia (VICTORY-S): study protocol for an interventional, open-label, randomized comparison of combined treatment with cognitive remediation and lurasidone or paliperidone.Frontiers in psychiatry · 2023Article
- Long-acting Injectable Antipsychotics during the COVID-19 pandemic in schizophrenia: An observational study in a real-world clinical setting.Psychiatry research · 2022Observational
- European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists · 2022Review
- Healthcare resource utilization and quality of life by cognitive impairment in patients with schizophrenia.Schizophrenia research. Cognition · 2022Article
- Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature.Frontiers in psychiatry · 2022Review
- Impact of COVID-19 Pandemic on Prescribing of Long-Acting Injectable Antipsychotics for Schizophrenia: Results from a United States Prescriber Survey.Neuropsychiatric disease and treatment · 2022Article
- The Basal Forebrain Cholinergic Nuclei and Their Relevance to Schizophrenia and Other Psychotic Disorders.Frontiers in psychiatry · 2022Review
- The Association Between Executive Functioning and Personal Recovery in People With Psychotic Disorders.Schizophrenia bulletin open · 2022Article
- Outcome prediction with a social cognitive battery: a multicenter longitudinal study.NPJ schizophrenia · 2021Article
- Mediation and moderation analyses: exploring the complex pathways between hope and quality of life among patients with schizophrenia.BMC psychiatry · 2020Article
- Deconstructing Avolition: Initiation vs persistence of reward-directed effort.Psychiatry research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Over the last several decades Quality of Life (QoL) has become increasingly important as an indicator of treatment outcomes; particularly in schizophrenia spectrum disorders because of its close association with functional disability. Numerous studies seeking to elucidate the factors that contribute to QoL in this population have implicated both symptom severity and cognition in determining QoL but the findings have been mixed. The critical factors that appear to impede the lack of consensus in the extant literature examining determinants of QoL include the heterogeneity of the samples and measures examined as well as medication effects across different studies. Thus, the present study sought to address some of these issues by examining the relationship between subjective QoL and both symptom severity and cognitive function in a relatively homogeneous patient sample of patients and a community control sample assessed for dimensional symptom severity. Our results suggest that both global cognitive function and psychiatric symptoms have a significant impact on the subjective QoL of both people with schizophrenia spectrum disorders and psychiatrically healthy adults. Specifically, we found that a global index of cognition as well as self-reported avolitional and depressive symptoms were significantly predictive of QoL in both samples. These findings highlight the importance of addressing cognitive, depressive and avolitional symptoms in the treatment of patients with schizophrenia spectrum disorders and suggest that improvements in these domains may have a meaningful impact on their overall QoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.